Raymond James Financial reissued their buy rating on shares of Spark Therapeutics (NASDAQ:ONCE) in a research note published on Tuesday morning.

A number of other research analysts have also weighed in on the company. Cantor Fitzgerald set a $105.00 price objective on Spark Therapeutics and gave the company a buy rating in a research report on Tuesday. Goldman Sachs Group lowered Spark Therapeutics from a buy rating to a neutral rating and cut their price objective for the company from $106.00 to $58.00 in a research report on Thursday, December 14th. They noted that the move was a valuation call. Barclays restated a buy rating and set a $54.00 price objective on shares of Spark Therapeutics in a research report on Wednesday, December 13th. Sanford C. Bernstein set a $71.00 price target on Spark Therapeutics and gave the stock a buy rating in a research report on Wednesday, December 13th. Finally, Wedbush upgraded Spark Therapeutics from an underperform rating to a neutral rating and dropped their price target for the stock from $65.00 to $50.00 in a research report on Tuesday, December 12th. They noted that the move was a valuation call. Two analysts have rated the stock with a sell rating, five have issued a hold rating and fifteen have issued a buy rating to the company. The company currently has a consensus rating of Buy and a consensus target price of $76.19.

Shares of Spark Therapeutics (NASDAQ ONCE) traded down $0.11 during trading on Tuesday, hitting $48.94. The stock had a trading volume of 2,933,300 shares, compared to its average volume of 502,297. Spark Therapeutics has a 52-week low of $41.06 and a 52-week high of $91.75.

Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.79) by ($0.11). The firm had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $1.40 million. Spark Therapeutics had a negative net margin of 1,090.11% and a negative return on equity of 60.01%. The company’s revenue for the quarter was up 45.8% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.07) EPS. sell-side analysts forecast that Spark Therapeutics will post -7.6 EPS for the current year.

In other Spark Therapeutics news, Director Hospital Of Philade Children’s sold 1,000,000 shares of the firm’s stock in a transaction dated Thursday, September 21st. The shares were sold at an average price of $84.63, for a total value of $84,630,000.00. Following the completion of the sale, the director now owns 3,928,707 shares of the company’s stock, valued at $332,486,473.41. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, insider Barge Joseph La sold 3,309 shares of the firm’s stock in a transaction dated Thursday, November 9th. The stock was sold at an average price of $71.31, for a total transaction of $235,964.79. Following the completion of the sale, the insider now directly owns 8,146 shares of the company’s stock, valued at approximately $580,891.26. The disclosure for this sale can be found here. In the last three months, insiders sold 1,067,309 shares of company stock valued at $89,681,885. 7.30% of the stock is owned by insiders.

Institutional investors have recently bought and sold shares of the company. JPMorgan Chase & Co. raised its stake in shares of Spark Therapeutics by 15.0% during the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock valued at $164,986,000 after acquiring an additional 241,016 shares in the last quarter. BlackRock Inc. raised its stake in shares of Spark Therapeutics by 11.6% during the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock valued at $122,689,000 after acquiring an additional 213,520 shares in the last quarter. Amundi Pioneer Asset Management Inc. bought a new stake in shares of Spark Therapeutics during the third quarter valued at approximately $5,286,000. TIAA CREF Investment Management LLC raised its stake in shares of Spark Therapeutics by 20.3% during the second quarter. TIAA CREF Investment Management LLC now owns 62,480 shares of the biotechnology company’s stock valued at $3,733,000 after acquiring an additional 10,544 shares in the last quarter. Finally, Balyasny Asset Management LLC raised its stake in shares of Spark Therapeutics by 104.8% during the second quarter. Balyasny Asset Management LLC now owns 59,400 shares of the biotechnology company’s stock valued at $3,549,000 after acquiring an additional 30,400 shares in the last quarter. 94.91% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY NOTICE: This article was originally published by Watch List News and is the property of of Watch List News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.watchlistnews.com/spark-therapeutics-once-buy-rating-reaffirmed-at-raymond-james-financial/1774656.html.

About Spark Therapeutics

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

Analyst Recommendations for Spark Therapeutics (NASDAQ:ONCE)

Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.